Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 05, 2021 12:38pm
168 Views
Post# 34199994

RE:RE:RE:Options

RE:RE:RE:Options From what I can tell from the proxy statements, it seems options grants were given in February or April in recent years.

Also, the size of these grants are larger than normal. Since there is not a lot achievements looking backward, it seems reasonable to assume these were given for something important that will soon happen and that the team has been working hard to achieve (cancer and/or NASH?). Hopefully, that is the case.

So, an educated guess is that we will soon hear good news of some sort as the company was evidently looking to get more options than normal into the hands of key executives sooner than normal. 

Which, as I said, also may explain why the company may have been quiet recently. They might not have wanted the share price to pop before they could get the options granted and they got that done as soon as they could once the new fiscal year started.   

SPCEO1 wrote: Maybe the options grants now tells us why they have been pretty quiet about the trial - they needed to get to the new fiscal year to grant options at a low price before announcing good results on the phase 1a or a partnership in cancer (or maybe even NASH).

palinc2000 wrote:

Tons of options at a very low low price!!!! I think the timing for the option grant is much earlier   Than previous years????
Is there a rush!!!!
The sickening part is that apparently all you need to qualify to receive options  is to be on the payroll

.

 

Thao977 wrote: Options has been granted on december 1st. At $4.21 CAN

 

 





<< Previous
Bullboard Posts
Next >>